Scholarlink

<p>Polyhydroxyalkanoates (PHAs), specifically polyhydroxybutyrate (PHB), are biodegradable polymers synthesized by various bacteria as energy. Unlike petrochemical-based plastics, PHAs are environmentally friendly and biocompatible. This study investigates a novel approach utilizing <i>Lactobacillus acidophilus</i> to produce PHB nanoparticles (PHB NPs), which holds promise for biomedical applications PHBs have advanced applications. The NPs exhibit small, uniform sizes and favorable zeta potential, making them ideal biotherapeutic carriers. The study focuses on optimizing PHB synthesis via microbial fermentation, where <i>L. acidophilus</i> cells were engineered to produce PHB NPs loaded with glatiramer acetate. In vitro and In vivo studies demonstrate the NPs’ efficacy in treating multiple sclerosis (MS). The findings suggest that these PHB NPs can potentially halt disease progression. Further pharmacodynamic and pharmacokinetic evaluations are crucial for advancing these NPs toward industrial applications in biomedicine. The goal is to utilize the produced PHB as a drug delivery system that is both biocompatible and capable of carrying active pharmaceutical ingredients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Lactobacillus acidophilus-Produced Polyhydroxybutyrate Nanoparticles: an Ideal Carrier for Multiple Sclerosis Treatment

  • 期刊论文

  • 发表日期：

    2025年3月20日

查看全文
  • Zahra Salarieh,
  • Akbar Esmaeili

摘要

Polyhydroxyalkanoates (PHAs), specifically polyhydroxybutyrate (PHB), are biodegradable polymers synthesized by various bacteria as energy. Unlike petrochemical-based plastics, PHAs are environmentally friendly and biocompatible. This study investigates a novel approach utilizing Lactobacillus acidophilus to produce PHB nanoparticles (PHB NPs), which holds promise for biomedical applications PHBs have advanced applications. The NPs exhibit small, uniform sizes and favorable zeta potential, making them ideal biotherapeutic carriers. The study focuses on optimizing PHB synthesis via microbial fermentation, where L. acidophilus cells were engineered to produce PHB NPs loaded with glatiramer acetate. In vitro and In vivo studies demonstrate the NPs’ efficacy in treating multiple sclerosis (MS). The findings suggest that these PHB NPs can potentially halt disease progression. Further pharmacodynamic and pharmacokinetic evaluations are crucial for advancing these NPs toward industrial applications in biomedicine. The goal is to utilize the produced PHB as a drug delivery system that is both biocompatible and capable of carrying active pharmaceutical ingredients.